IUPAC name
2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
SMILES
CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F
Compound class
Antineoplastic Agents, Hormonal; Androgen Antagonists; Antineoplastic and Immunomodulating Agents; Endocrine Therapy; Hormone Antagonists and Related Agents; Anti-Androgens; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP2C19 Inducers; CYP3A4 Inhibitors;
Therapeutic area
For the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate.
Common name
Flutamide
IUPAC name
2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
SMILES
CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F
INCHI
InChI=1S/C11H11F3N2O3/c1-6(2)10(17)15-7-3-4-9(16(18)19)8(5-7)11(12,13)14/h3-6H,1-2H3,(H,15,17)
FORMULA
C11H11F3N2O3
Common name
Flutamide
IUPAC name
2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
Molecular weight
276.212
clogP
2.020
clogS
-3.659
HBond Acceptor
3
HBond Donor
1
Total Polar Surface Area
80.91
Number of Rings
1
Rotatable Bond
4
| Drug ID | Common name | Structure CAS | SMILE | Frequency |
|---|---|---|---|---|
| FDBF00003 | formamide |
|
C(=O)N | 0.1240 |
| FDBF00007 | propane |
|
C(C)C | 0.2412 |
| FDBF00177 | fluoroform |
|
FC(F)F | 0.0704 |
| FDBF00334 | 2-methylpropanamide |
|
CC(C)C(=O)N | 0.0027 |
| FDBF00779 | nitrobenzene |
|
O=N(=O)c1ccccc1 | 0.0134 |
| FDBF01107 | 1-nitro-2-(trifluoromethyl)benzene |
|
FC(F)(F)c1ccccc1N(=O)=O | 0.0007 |
